SK1-I
- CAS No.
- 1072443-89-0
- Chemical Name:
- SK1-I
- Synonyms
- SK1-I;BML258;BML-258;BML 258;BML-258 HCl;D-erythro-Pent-1-enitol, 1,2,4-trideoxy-4-(methylamino)-1-(4-pentylphenyl)-, (1E)-
- CBNumber:
- CB12535697
- Molecular Formula:
- C17H27NO2
- Molecular Weight:
- 277.41
- MDL Number:
- MOL File:
- 1072443-89-0.mol
- MSDS File:
- SDS
SK1-I price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | XSB44389 | BML-258 | 1072443-89-0 | 1mg | $250 | 2026-06-05 | Buy |
| Biosynth | XSB44389 | BML-258 | 1072443-89-0 | 5mg | $400.8 | 2026-06-05 | Buy |
| Biosynth | XSB44389 | BML-258 | 1072443-89-0 | 10mg | $641.2 | 2026-06-05 | Buy |
| Biosynth | XSB44389 | BML-258 | 1072443-89-0 | 25mg | $1202.5 | 2026-06-05 | Buy |
| Biosynth | XSB44389 | BML-258 | 1072443-89-0 | 50mg | $1923.5 | 2026-06-05 | Buy |
SK1-I Chemical Properties, Uses, Production
Uses
SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 μM[1]. SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity[2].
in vivo
Pre-treatment with SK1-I (BML-258; intraperitoneal (i.p.) injection; once; 24 hours prior to baseline mean arterial blood pressure (MAP) measurement; 75 mg/kg) before anandamide (i.v. injection; two doses; 1 and 10 mg/kg) significantly decreases the hypotensive response[3].
| Animal Model: | Male C57BL/6 mice (24±3.5g) [3] |
| Dosage: | 75 mg/kg |
| Administration: | Intraperitoneal (i.p.) injection; once; 24 hours prior to baseline MAP measurement |
| Result: | Significantly lowered baseline mean arterial blood pressure (MAP). |
IC 50
SphK1
References
[1] Melissa R Pitman, et al. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets. 2010 Jun;10(4):354-67. DOI:10.2174/156800910791208599
[2] Santiago Lima, et al. TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition. Autophagy. 2018;14(6):942-957. DOI:10.1080/15548627.2018.1429875
[3] Fiona H Greig, et al. Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse. Eur J Pharmacol. 2019 Jan 5;842:1-9. DOI:10.1016/j.ejphar.2018.10.027
SK1-I Preparation Products And Raw materials
Raw materials
Preparation Products
SK1-I Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| EMMX Biotechnology LLC | 888-539-0666 | info@emmx.com | United States | 8435 | 60 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9799 | 58 |
| Guangzhou Younan Technology Co., Ltd | 020-82000279 18988941452 | YN_research@163.com | China | 2984 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Zhejiang Huida Biotech Co., Ltd. | 0571-89903022 18679456698 | zilong@hizyme.com | China | 7853 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 38999 | 58 |
